Uncategorized
International Study Demonstrates Potential for Titratable Treatment with 1, 2 or 3 Glaukos iStent® Trabecular Micro-Bypass Stents in Open-Angle Glaucoma Patients
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that a new international study, published in the December 2015 issue of Clinical Ophthalmology, showed that patients achieved significantly greater reduction in intraocular pressure (IOP) at 18 months with use of each additional iS
